ALLHAT education campaign
Executive Summary
The National Heart, Lung and Blood Institute announces a three year, $3.7 mil. initiative to educate physicians and patients about hypertension findings from the ALLHAT trial. The study's main finding was that generic diuretic chlorthalidone is superior to Pfizer's calcium channel blocker Norvasc (amlodipine) and ACE inhibitors in preventing cardiovascular outcomes. The campaign, funded by NHLBI, will be implemented in collaboration with the National High Blood Pressure Education Program. Approximately 150 physicians in 34 states have completed training to lead educational sessions with physician peers. Educators will conduct one session per month and are expected to reach nearly 30,000 physicians by September 2006. Cardiologists have expressed concern about the translation of ALLHAT findings into clinical practice. (1"The Pink Sheet" June 27, 2005, p. 20)...
You may also be interested in...
Antihypertensive Cardio Labeling Should Be Applied To New Classes – Cmte.
Class labeling for reduction of cardiovascular outcomes based on blood pressure lowering should be applied to new classes of antihypertensives, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.